Saskatchewan SARS-CoV-2 Seroprevalence Study
The primary objective of this study is to measure the seroprevalence of antibodies to COVID-19 in Saskatchewan by geographic area, age group and sex in order to ascertain the cumulative population immunity.
Secondary objectives of this study are:
* To target immunization priorities to areas of the province with low seroprevalence rates,
* To estimate the fraction of vaccine-induced immunity versus natural infection,
* To examine duration of protection at a population-level by analyzing the association between antibody titer levels and length of time since immunization,
* To compare provincial population immunity to SARS-CoV-2 pre and post-immunization and pre and post Variant of Concern (VoC) importation.
Overview
- Acronym
- SaskCov
- Investigators
-
- Contacts
-
General Design
- Study design
- Cross-sectional
- Start - End Year
- 2020 - 2023
- General Information on Follow Up (profile, frequency)
-
A random sample of serum collected for the purposes of TSH and Cholesterol testing in the province of Saskatchewan during two time periods, Phase 1 from May to December 2020 and Phase 2 from October 2021 to June 2022, will be tested for antibodies to SARS-CoV-2.
- Recruitment Target
-
- Individuals
- Number of Participants
- 20,000
- Number of Participants with Biological Samples
- 20,000
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Timeline
Population
SaskCov population
The population is composed of individuals who have their blood samples collected for the purposes of TSH and Cholesterol testing from laboratories across Saskatchewan.
Selection Criteria
- Countries
-
- Canada
- Canadian Provinces
-
- Saskatchewan
- Territory
- Saskatchewan
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
A random selection of residual serum samples collected for the purposes of TSH and Cholesterol testing will be analyzed for antibodies to SARS-CoV-2.
Sample Size
- Number of Participants
- 20,000
- Number of Participants with Biological Samples
- 20,000
- Supplementary information about number of participants
-
Phase I collection: 10,000 samples
Phase II collection: 10,000 samples
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SaskCov - Phase I Collection |
|
|
2020 (May) | 2020 (December) |
| 1 | SaskCov - Phase II Collection |
|
|
2021 (October) | 2022 (June) |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2022-03-23T11:23:38.464